{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T06:11:54Z","timestamp":1672380714084},"reference-count":22,"publisher":"The University of Occupational and Environmental Health, Japan","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J UOEH"],"published-print":{"date-parts":[[2021,6,1]]},"DOI":"10.7888\/juoeh.43.255","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T22:14:41Z","timestamp":1622758481000},"page":"255-261","source":"Crossref","is-referenced-by-count":0,"title":["A Case of Neuromyelitis Optica Spectrum Disorder Who Relapsed Under Oral Corticosteroid Treatment with Multiple Cerebrospinal Lesions and Severe Neurological Deficits"],"prefix":"10.7888","volume":"43","author":[{"given":"Yuri","family":"UEMOTO","sequence":"first","affiliation":[{"name":"Department of Neurology, Kokura Memorial Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"SHIRAISHI","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kokura Memorial Hospital, Japan"},{"name":"Shiraishi Internal Medicine Clinic, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"FUJIKI","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kokura Memorial Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konosuke","family":"FURUTA","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kokura Memorial Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4637","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF & Weinshenker BG (2006): Revised diagnostic criteria for neuromyelitis optica. Neurology 66(10): 1485\u22121489","DOI":"10.1212\/01.wnl.0000216139.44259.74"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Wingerchuk DM, Banwell B, Bennett JL <i>et al<\/i> (2015): International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2): 177\u2212189","DOI":"10.1212\/WNL.0000000000001729"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Lennon VA, Wingerchuk DM, Kryzer TJ <i>et al<\/i> (2004): A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364 (9451): 2106\u22122112","DOI":"10.1016\/S0140-6736(04)17551-X"},{"key":"4","unstructured":"4. \u6e21\u9089\u5145\uff082019\uff09: \u3010\u3055\u307e\u3056\u307e\u306a\u795e\u7d4c\u7b4b\u75be\u60a3\u3092\u7406\u89e3\u3059\u308b\u3011\u591a\u767a\u6027\u786c\u5316\u75c7\u3068\u985e\u7e01\u75be\u60a3\uff0e\u30c7\u30a3\u30b5\u30fc\u30b9\u30ea\u30a2\u81e8\u5e8a\u7814\u7a76 9(1): 46\u221252"},{"key":"5","unstructured":"5. \u4e2d\u5cf6\u4e00\u90ce\uff082020\uff09: \u3010\u795e\u7d4c\u96e3\u75c5\u3092\u30af\u30b9\u30ea\u3067\u6cbb\u3059\uff0d\u85ac\u7269\u958b\u767a\u306e\u73fe\u6cc1\u3068\u8fd1\u672a\u6765\u3078\u306e\u5c55\u671b\u3011\u8996\u795e\u7d4c\u810a\u9ac4\u708e\u30b9\u30da\u30af\u30c8\u30e9\u30e0\u969c\u5bb3\u6cbb\u7642\u306e\u5c55\u671b\uff0eBRAIN and NERVE: \u795e\u7d4c\u7814\u7a76\u306e\u9032\u6b69 72(1): 61\u221268"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Yamasaki R, Matsushita T, Fukazawa T <i>et al<\/i> (2016): Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica. Mult Scler 22(10): 1337\u22121348","DOI":"10.1177\/1352458515617248"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kitley J, Leite MI, Nakashima I <i>et al<\/i> (2012): Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 135 (Pt 6): 1834\u22121849","DOI":"10.1093\/brain\/aws109"},{"key":"8","unstructured":"8. \u67f3\u6751\u6587\u5bdb\uff0c\u6cb3\u5185\u6cc9\uff0c\u897f\u6fa4\u6b63\u8c4a \uff082015\uff09: NMO\u306e\u8a3a\u65ad\u3068\u6cbb\u7642\uff0e\u533b\u5b66\u306e\u3042\u3086\u307f 255: 390\u2212396"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Takai Y, Misu T, Nakashima I <i>et al<\/i> (2012): Two cases of lumbosacral myeloradiculitis with anti-aquaporin-4 antibody. Neurology 79(17): 1826\u22121828","DOI":"10.1212\/WNL.0b013e3182703ff7"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kim S, Park J, Kwon BS <i>et al<\/i> (2017): Radiculopathy in neuromyelitis optica. How does anti-AQP4 Ab involve PNS? Mult Scler Relat Disord 18: 77\u221281","DOI":"10.1016\/j.msard.2017.09.006"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. He M, Gao D, Zhang J, Huang D, Tian Y & Yu S (2019): Suspected bacterial meningoencephalomyelitis as the trigger or presentation of neuromyelitis optica spectrum disorder flare. Mult Scler Relat Disord 30: 38\u221241","DOI":"10.1016\/j.msard.2019.01.050"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. \u85e4\u5009\u821e\uff0c\u6a2a\u5ddd\u548c\u6a39\uff0c\u9759\u5ddd\u88d5\u5f66\uff0c\u4e0b\u6ff1\u4fca\uff082016\uff09: \u8457\u660e\u306a\u9ac4\u6db2\u7d30\u80de\u6570\u5897\u52a0\u3068\u9ac4\u6db2\u7cd6\u4f4e\u4e0b\u3092\u5448\u3057\u305f\u8996\u795e\u7d4c\u810a\u9ac4\u708e\u306e1\u4f8b\uff0e\u81e8\u5e8a\u795e\u7d4c\u5b66 56(8): 569\u2212572","DOI":"10.5692\/clinicalneurol.cn-000753"},{"key":"13","unstructured":"13. \u5c0f\u53e3\u7d62\u5b50\uff0c\u5e73\u91ce\u96c4\u5927\uff0c\u5824\u767e\u5408\uff0c\u5824\u5185\u8def\u5b50\uff0c\u4e0a\u5742\u7fa9\u548c \uff082018\uff09: \u60aa\u5bd2\u6226\u6144\u306b\u3066\u767a\u75c7\u3057\u6025\u901f\u9032\u884c\u6027\u306e\u610f\u8b58\u969c\u5bb3\uff0c\u56db\u80a2\u9ebb\u75fa\uff0c\u6392\u5c3f\u969c\u5bb3\u3092\u5448\u3057\u305f\u8996\u795e\u7d4c\u810a\u9ac4\u708e\u306e1\u4f8b\uff0eJournal of Japan Society of Neurological Emergencies & Critical Care 30(2): 73\u221277"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Sellner J, Boggild M, Clanet M <i>et al<\/i> (2010): EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 17(8): 1019\u22121032","DOI":"10.1111\/j.1468-1331.2010.03066.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Lepur D, Peterkovic V & Kalabric-Lepur N (2009): Neuromyelitis optica with CSF examination mimicking bacterial meningomyelitis. Neurol Sci 30(1): 51\u221254","DOI":"10.1007\/s10072-008-0002-x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. B\u00e9langer M, Allaman I & Magistretti PJ (2011): Differential effects of pro- and anti-inflammatory cytokines alone or in combinations on the metabolic profile of astrocytes. J Neurochem 116(4): 564\u2212576","DOI":"10.1111\/j.1471-4159.2010.07135.x"},{"key":"17","unstructured":"17. \u5317\u30ce\u5712\u5bdb\u5b50\uff0c\u5ca9\u6c38\u6d0b\uff0c\u6848\u6d66\u82b1\u5948\u5b50\uff0c\u5cf6\u667a\u79cb\uff0c\u798f\u5cf6\u76f4\u7f8e\uff0c\u8fbb\u91ce\u5f70 \uff082018\uff09: \u9ac4\u6db2\u7cd6\u4f4e\u4e0b\u3092\u5448\u3057\u305f\u8996\u795e\u7d4c\u810a\u9ac4\u708e\u95a2\u9023\u75be\u60a3\u306e1\u4f8b\uff0eBRAIN and NERVE: \u795e\u7d4c\u7814\u7a76\u306e\u9032\u6b69 70(10): 1115\u22121118"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Akman-Demir G, Tuzun E, Waters P <i>et al<\/i> (2011): Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients. J Neurol 258(3): 464\u2212470","DOI":"10.1007\/s00415-010-5780-4"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Noval S, Oreja-Guevara C & Contreras I (2013): Monitoring neuromyelitis optica activity. Expert Rev Neurother 13(9): 989\u2212999","DOI":"10.1586\/14737175.2013.832850"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Watanabe S, Misu T, Miyazawa I <i>et al<\/i> (2007): Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 13(8): 968\u2212974","DOI":"10.1177\/1352458507077189"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Tackley G, O\u02bcBrien F, Rocha J <i>et al<\/i> (2016): Neuromyelitis optica relapses: Race and rate, immunosuppression and impairment. Mult Scler Relat Disord 7: 21\u221225","DOI":"10.1016\/j.msard.2016.02.014"},{"key":"22","unstructured":"22. \u65e5\u672c\u795e\u7d4c\u5b66\u4f1a\uff082017\uff09: \u591a\u767a\u6027\u786c\u5316\u75c7\u30fb\u8996\u795e\u7d4c\u810a\u9ac4\u708e\u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f32017\uff0e\uff08\u300c\u591a\u767a\u6027\u786c\u5316\u75c7\u30fb\u8996\u795e\u7d4c\u810a\u690e\u708e\u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u300d\u4f5c\u6210\u59d4\u54e1\u4f1a\u3000\u7de8\uff09\uff0c\u533b\u5b66\u66f8\u9662\uff0c\u6771\u4eac 352 pp"}],"container-title":["Journal of UOEH"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/juoeh\/43\/2\/43_255\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T18:38:27Z","timestamp":1672339107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/juoeh\/43\/2\/43_255\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.7888\/juoeh.43.255","relation":{},"ISSN":["0387-821X","2187-2864"],"issn-type":[{"value":"0387-821X","type":"print"},{"value":"2187-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,1]]}}}